,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,1189,1,5,,48414504,15625,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary SingleCellCall Results,Other,,
1,1194,1,3,,48414504,15625,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Salmonella Mutagenicity,Other,,
2,1199,1,3,,48414504,15625,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Mouse Bioassay Results,Other,,
3,1205,1,4,,48414504,15625,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary MultiCellCall Results,Other,,
4,1208,1,3,,48414504,15625,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Rat Bioassay Results,Other,,
5,39064,6,2,,103204055,15625,Active,,,0.01,EC50,Affinity on cytosolic Aromatic hydrocarbon receptor (Ah),Confirmatory,9435905.0,
6,39092,3,8,,103204055,15625,Active,,,,,Compound tested for its binding to human Orphan receptor (AhR); Active,Other,14684315.0,
7,169707,3,3,,103204055,15625,Unspecified,,,,,Number of T4 binding sites in rat liver from TCDD treated rats,Other,3100800.0,
8,169708,3,3,,103204055,15625,Unspecified,,,,,Number of T4 binding sites in rat liver from TCDD treated rats at a dose of 12 ug/Kg,Other,3100800.0,
9,169709,3,3,,103204055,15625,Unspecified,,,,,Number of T4 binding sites in rat liver from TCDD treated rats at a dose of 25 ug/Kg,Other,3100800.0,
10,169710,3,3,,103204055,15625,Unspecified,,,,,Number of T4 binding sites in rat liver from TCDD treated rats at a dose of 37 ug/Kg,Other,3100800.0,
11,169711,3,3,,103204055,15625,Unspecified,,,,,Number of T4 binding sites in rat liver from TCDD treated rats at a dose of 50 ug/Kg,Other,3100800.0,
12,196193,5,3,,103204055,15625,Unspecified,,,,,Serum T4 level was determined in TCDD-treated rat at a dose of 12 ug/Kg,Other,3100800.0,
13,196194,5,3,,103204055,15625,Unspecified,,,,,Serum T4 level was determined in TCDD-treated rat at a dose of 25 ug/Kg,Other,3100800.0,
14,196195,5,3,,103204055,15625,Unspecified,,,,,Serum T4 level was determined in TCDD-treated rat at a dose of 37 ug/kg,Other,3100800.0,
15,196196,5,3,,103204055,15625,Unspecified,,,,,Serum T4 level was determined in TCDD-treated rat at a dose of 50 ug/Kg,Other,3100800.0,
16,196197,5,3,,103204055,15625,Unspecified,,,,,Serum T4 level was determined in rats,Other,3100800.0,
17,197219,3,4,,103204055,15625,Unspecified,,,,,Body weight (after treatment) was determined,Other,3100800.0,
18,197220,3,4,,103204055,15625,Unspecified,,,,,Body weight was determined in TCDD-treated rat at a dose of 12 ug/Kg,Other,3100800.0,
19,197221,3,4,,103204055,15625,Unspecified,,,,,Body weight was determined in TCDD-treated rats at a dose of 25 ug/Kg,Other,3100800.0,
20,197222,3,4,,103204055,15625,Unspecified,,,,,Body weight was determined in TCDD-treated rats at a dose of 37 ug/Kg,Other,3100800.0,
21,197223,3,4,,103204055,15625,Unspecified,,,,,Body weight was determined in TCDD-treated rats at a dose of 50 ug/Kg,Other,3100800.0,
22,197224,3,4,,103204055,15625,Unspecified,,,,,Liver weight was determined in TCDD-treated rat at a dose of 12 ug/Kg,Other,3100800.0,
23,197225,3,4,,103204055,15625,Unspecified,,,,,Liver weight was determined in TCDD-treated rats at a dose of 25 ug/Kg,Other,3100800.0,
24,197226,3,4,,103204055,15625,Unspecified,,,,,Liver weight was determined in TCDD-treated rats at a dose of 37 ug/Kg,Other,3100800.0,
25,197227,3,4,,103204055,15625,Unspecified,,,,,Liver weight was determined in TCDD-treated rats at a dose of 50 ug/Kg,Other,3100800.0,
26,197228,3,4,,103204055,15625,Unspecified,,,,,Liver weight was determined in rats,Other,3100800.0,
27,210547,4,4,,103204055,15625,Active,,,0.0007,Kd,Binding affinity of [125I]T4 to rat liver nuclear extract (CONTROL),Confirmatory,3100800.0,
28,210548,4,4,,103204055,15625,Active,,,0.00047999999999999996,Kd,Binding affinity of [125I]T4 to rat liver nuclear extract at a dose of 12 ug/Kg,Confirmatory,3100800.0,
29,210549,4,4,,103204055,15625,Active,,,0.00056,Kd,Binding affinity of [125I]T4 to rat liver nuclear extract at a dose of 25 ug/Kg,Confirmatory,3100800.0,
30,210550,4,3,,103204055,15625,Active,,,0.0006900000000000001,Kd,Binding affinity of [125I]-T4 to rat liver nuclear extract at a dose of 37 ug/Kg,Confirmatory,3100800.0,
31,210551,4,4,,103204055,15625,Active,,,0.00072,Kd,Binding affinity of [125I]T4 to rat liver nuclear extract at a dose of 50 ug/Kg,Confirmatory,3100800.0,
32,431863,3,9,,103204055,15625,Unspecified,29337198.0,11622.0,,,Induction of mouse AhR LBD transcriptional activity in mouse hepa1 cells transfected with AhR response element co expressed with XRE after 6 hrs by luciferase reporter gene assay relative to control,Other,19719119.0,
33,433903,3,3,,103204055,15625,Unspecified,,,,,Hepatotoxicity in mouse assessed as carcinogenic potency,Other,19272677.0,
34,467952,3,4,,103204055,15625,Active,,,,,Induction of CYP1B1 expression in human MCF7 cells at 10 nM after 24 hrs by 7-ethoxyresorufin-O-deethelase assay,Other,19601638.0,
35,588209,2,3,,103204055,15625,Unspecified,,,,,Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset,Other,20553011.0,
36,589028,1,8,,103204055,15625,Unspecified,,,,,Aryl hydrocarbon receptor agonist (species not specified),Other,,
37,589049,1,10,,103204055,15625,Unspecified,117144.0,1544.0,,,"Clinically relevant inducers of human liver microsomal P450 enzymes, isoform CYP1A2",Other,,
38,625144,5,5,,103204055,15625,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
39,625145,4,7,,103204055,15625,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
40,625146,5,5,,103204055,15625,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
41,625147,4,7,,103204055,15625,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
42,625148,4,7,,103204055,15625,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
43,625149,4,7,,103204055,15625,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
44,625150,5,5,,103204055,15625,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
45,625151,4,7,,103204055,15625,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
46,625152,4,7,,103204055,15625,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
47,625153,4,7,,103204055,15625,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
48,625154,4,7,,103204055,15625,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
49,625155,4,7,,103204055,15625,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
50,625156,1,9,,103204055,15625,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
51,625157,6,2,,103204055,15625,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
52,625158,3,4,,103204055,15625,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
53,625159,5,5,,103204055,15625,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
54,625160,1,9,,103204055,15625,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
55,625161,4,7,,103204055,15625,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
56,625162,4,7,,103204055,15625,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
57,625163,4,7,,103204055,15625,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
58,625164,1,6,,103204055,15625,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
59,625165,3,4,,103204055,15625,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
60,625166,3,4,,103204055,15625,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
61,625167,5,5,,103204055,15625,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
62,625168,4,7,,103204055,15625,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
63,625169,1,6,,103204055,15625,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
64,625170,3,4,,103204055,15625,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
65,625171,4,7,,103204055,15625,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
66,625172,4,7,,103204055,15625,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
67,625173,5,5,,103204055,15625,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
68,625174,5,5,,103204055,15625,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
69,625175,5,5,,103204055,15625,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
70,625176,1,9,,103204055,15625,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
71,625177,5,5,,103204055,15625,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
72,625178,5,5,,103204055,15625,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
73,625179,1,9,,103204055,15625,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
74,625180,5,5,,103204055,15625,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
75,625181,5,5,,103204055,15625,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
76,625182,5,5,,103204055,15625,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
77,625183,5,5,,103204055,15625,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
78,625184,5,5,,103204055,15625,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
79,625185,5,5,,103204055,15625,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
80,625186,5,5,,103204055,15625,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
81,625187,5,5,,103204055,15625,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
82,625188,1,9,,103204055,15625,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
83,625189,1,7,,103204055,15625,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
84,625190,4,5,,103204055,15625,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
85,625191,4,7,,103204055,15625,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
86,625192,4,7,,103204055,15625,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
87,625193,5,5,,103204055,15625,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
88,625194,4,7,,103204055,15625,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
89,625195,4,7,,103204055,15625,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
90,625196,5,6,,103204055,15625,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
91,625197,3,4,,103204055,15625,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
92,625198,4,7,,103204055,15625,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
93,625199,4,7,,103204055,15625,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
94,625200,4,7,,103204055,15625,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
95,625201,4,7,,103204055,15625,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
96,625202,4,7,,103204055,15625,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
97,625203,4,7,,103204055,15625,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
98,625204,4,7,,103204055,15625,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
99,625205,4,7,,103204055,15625,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
100,625206,4,7,,103204055,15625,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
101,625207,4,7,,103204055,15625,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
102,625208,5,5,,103204055,15625,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
103,625209,4,7,,103204055,15625,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
104,625210,3,4,,103204055,15625,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
105,625211,1,6,,103204055,15625,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
106,625212,3,4,,103204055,15625,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
107,625213,4,7,,103204055,15625,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
108,625214,1,9,,103204055,15625,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
109,625215,3,4,,103204055,15625,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
110,625216,3,4,,103204055,15625,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
111,625217,4,7,,103204055,15625,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
112,625218,4,7,,103204055,15625,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
113,625219,3,4,,103204055,15625,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
114,625220,4,7,,103204055,15625,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
115,625221,4,7,,103204055,15625,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
116,625222,4,7,,103204055,15625,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
117,625223,4,7,,103204055,15625,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
118,625224,3,4,,103204055,15625,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
119,625225,3,4,,103204055,15625,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
120,625226,4,7,,103204055,15625,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
121,625227,4,7,,103204055,15625,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
122,625228,4,7,,103204055,15625,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
123,625229,5,5,,103204055,15625,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
124,625230,1,6,,103204055,15625,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
125,625231,4,7,,103204055,15625,Active,143811474.0,2321.0,0.0026899999999999997,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
126,625232,1,9,,103204055,15625,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
127,625233,4,7,,103204055,15625,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
128,625234,3,4,,103204055,15625,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
129,625235,4,7,,103204055,15625,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
130,625236,5,5,,103204055,15625,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
131,625237,4,7,,103204055,15625,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
132,625238,4,7,,103204055,15625,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
133,625239,4,7,,103204055,15625,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
134,625240,1,9,,103204055,15625,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
135,625241,4,7,,103204055,15625,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
136,625242,4,7,,103204055,15625,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
137,625243,5,5,,103204055,15625,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
138,625244,5,5,,103204055,15625,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
139,625245,5,5,,103204055,15625,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
140,625246,1,9,,103204055,15625,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
141,625247,5,5,,103204055,15625,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
142,625248,5,5,,103204055,15625,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
143,625249,5,5,,103204055,15625,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
144,625250,5,5,,103204055,15625,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
145,625251,5,5,,103204055,15625,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
146,625252,4,7,,103204055,15625,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
147,625253,4,7,,103204055,15625,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
148,625254,4,7,,103204055,15625,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
149,625255,4,7,,103204055,15625,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
150,625256,4,7,,103204055,15625,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
151,625257,4,7,,103204055,15625,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
152,625258,4,7,,103204055,15625,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
153,625259,4,7,,103204055,15625,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
154,625260,3,4,,103204055,15625,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
155,625261,3,4,,103204055,15625,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
156,625262,3,4,,103204055,15625,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
157,625263,4,7,,103204055,15625,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
158,625264,3,4,,103204055,15625,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
159,625265,1,6,,103204055,15625,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
160,625266,3,4,,103204055,15625,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
161,625267,3,4,,103204055,15625,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
162,625268,4,2,,103204055,15625,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
163,625268,4,2,,103204055,15625,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
164,625268,4,2,,103204055,15625,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
165,625268,4,2,,103204055,15625,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
166,625269,4,7,,103204055,15625,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
167,625270,4,7,,103204055,15625,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
168,625271,5,5,,103204055,15625,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
169,625272,3,4,,103204055,15625,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
170,625273,4,6,,103204055,15625,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
171,625274,1,6,,103204055,15625,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
172,625275,3,4,,103204055,15625,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
173,631103,5,2,,103204055,15625,Active,29337198.0,11622.0,2.9999999999999997e-05,EC50,Agonist activity at Ah receptor in genetically engineered mouse cells expressing firefly luciferase gene by CALUX transactivational assay,Confirmatory,21958547.0,
174,651631,4,1,,144209990,15625,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
175,651632,4,1,,144209990,15625,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
176,651633,4,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
177,651634,4,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
178,678816,1,7,,103204055,15625,Unspecified,81911503.0,,,,TP_TRANSPORTER: Northern blot in vivo Fischer male rat,Other,2845109.0,
179,682136,1,8,,103204055,15625,Unspecified,3914190.0,170698.0,,,"TP_TRANSPORTER: Western in vivo SD rat, liver",Other,11752118.0,
180,720516,2,1,,144209990,15625,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
181,720552,2,1,,144209990,15625,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
182,720634,2,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
183,720635,2,1,,144209990,15625,Inconclusive,,,0.0053,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
184,720637,2,1,,144209990,15625,Inconclusive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
185,720674,2,2,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
186,720675,2,2,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
187,720678,2,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
188,720679,2,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
189,720680,2,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
190,720681,2,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
191,720682,2,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
192,720683,2,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
193,720684,2,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
194,720685,2,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
195,720686,2,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
196,720687,2,2,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
197,720691,4,1,,144209990,15625,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
198,720692,3,1,,144209990,15625,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
199,720693,3,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
200,720719,2,1,,144209990,15625,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
201,720725,2,1,,144209990,15625,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
202,743012,3,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
203,743014,3,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
204,743015,3,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
205,743033,3,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
206,743035,2,1,,144209990,15625,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
207,743036,2,1,,144209990,15625,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
208,743040,3,1,,144209990,15625,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
209,743041,3,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
210,743042,3,1,,144209990,15625,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
211,743053,2,1,,144209990,15625,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
212,743054,2,1,,144209990,15625,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
213,743063,2,1,,144209990,15625,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
214,743064,3,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
215,743065,3,1,,144209990,15625,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
216,743066,3,1,,144209990,15625,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
217,743067,2,1,,144209990,15625,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
218,743069,2,1,,144209990,15625,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
219,743074,2,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
220,743075,2,1,,144209990,15625,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
221,743077,2,1,,144209990,15625,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
222,743078,2,1,,144209990,15625,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
223,743079,3,1,,144209990,15625,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
224,743080,3,1,,144209990,15625,Active,348019627.0,2099.0,0.0007,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
225,743081,3,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
226,743083,3,1,,144209990,15625,Inconclusive,119597822.0,1588.0,0.0011,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
227,743084,3,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
228,743085,3,1,,144209990,15625,Active,51095037.0,196.0,0.0011,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
229,743086,3,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
230,743091,2,1,,144209990,15625,Active,348019627.0,2099.0,0.000316212,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
231,743094,3,1,,144209990,15625,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
232,743122,2,1,,144209990,15625,Active,51095037.0,196.0,0.0006944560000000001,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
233,743139,2,1,,144209990,15625,Inconclusive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
234,743140,2,1,,144209990,15625,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
235,743191,3,1,,144209990,15625,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
236,743194,3,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
237,743199,2,1,,144209990,15625,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
238,743202,4,1,,144209990,15625,Inconclusive,20149576.0,4780.0,0.0001,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
239,743203,3,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
240,743209,3,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
241,743210,4,1,,144209990,15625,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
242,743211,3,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
243,743212,3,1,,144209990,15625,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
244,743213,3,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
245,743215,3,1,,144209990,15625,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
246,743217,3,1,,144209990,15625,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
247,743218,3,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
248,743219,3,1,,144209990,15625,Active,20149576.0,4780.0,0.000595632,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
249,743220,3,1,,144209990,15625,Inconclusive,325495553.0,9971.0,0.2132,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
250,743221,3,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
251,743222,3,1,,144209990,15625,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
252,743223,3,1,,144209990,15625,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
253,743224,3,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
254,743225,3,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
255,743226,2,1,,144209990,15625,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
256,743227,2,1,,144209990,15625,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
257,743228,3,1,,144209990,15625,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
258,743239,2,1,,144209990,15625,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
259,743240,2,1,,144209990,15625,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
260,743241,2,1,,144209990,15625,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
261,743242,2,1,,144209990,15625,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
262,924555,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: R030409,Other,,
263,924556,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: R030409,Other,,
264,924557,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: R030409,Other,,
265,924558,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: R030409,Other,,
266,924559,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: R030409,Other,,
267,924560,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: R030409,Other,,
268,924561,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: R030409,Other,,
269,924562,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: R030409,Other,,
270,924563,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: R030409,Other,,
271,924564,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: R030409",Other,,
272,924565,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: R030409,Other,,
273,924566,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: R030409,Other,,
274,924567,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: R030409,Other,,
275,924568,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: R030409,Other,,
276,924569,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: R030409,Other,,
277,924570,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: R030409,Other,,
278,924571,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: R030409,Other,,
279,924572,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: R030409,Other,,
280,924573,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: R030409,Other,,
281,924574,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: R030409,Other,,
282,924575,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: R030409,Other,,
283,924576,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: R030409,Other,,
284,924577,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: R030409,Other,,
285,924578,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: R030409,Other,,
286,924579,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: R030409,Other,,
287,924580,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: R030409,Other,,
288,924769,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: R030409,Other,,
289,924770,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: R030409,Other,,
290,924771,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: R030409,Other,,
291,924772,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: R030409",Other,,
292,924773,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: R030409,Other,,
293,924774,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: R030409,Other,,
294,924775,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: R030409,Other,,
295,924776,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: R030409,Other,,
296,924777,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: R030409,Other,,
297,924778,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: R030409,Other,,
298,925760,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: R030916,Other,,
299,925761,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: R030916,Other,,
300,925762,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: R030916,Other,,
301,925763,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: R030916,Other,,
302,925764,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: R030916,Other,,
303,925765,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: R030916,Other,,
304,925766,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: R030916,Other,,
305,925767,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: R030916,Other,,
306,925768,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: R030916,Other,,
307,925769,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: R030916,Other,,
308,925770,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: R030916,Other,,
309,925771,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: R030916,Other,,
310,925772,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: R030916,Other,,
311,930875,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: R030916,Other,,
312,930876,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: R030916,Other,,
313,930877,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: R030916,Other,,
314,930878,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: R030916,Other,,
315,930879,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: R030916,Other,,
316,930880,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: R030916,Other,,
317,930881,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: R030916,Other,,
318,930882,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: R030916,Other,,
319,930883,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: R030916,Other,,
320,930884,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: R030916,Other,,
321,930885,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: R030916,Other,,
322,930886,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: R030916,Other,,
323,931514,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: R030916,Other,,
324,949240,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: R030409,Other,,
325,949241,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: R030409,Other,,
326,949242,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: R030409,Other,,
327,949243,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: R030409,Other,,
328,949244,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: R030409,Other,,
329,949245,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: R030409",Other,,
330,949246,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: R030409,Other,,
331,949247,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: R030409,Other,,
332,949248,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: R030409,Other,,
333,949249,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: R030409,Other,,
334,949250,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: R030409,Other,,
335,949251,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: R030409,Other,,
336,949252,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: R030409,Other,,
337,949253,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: R030409,Other,,
338,949254,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: R030409,Other,,
339,949255,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: R030409,Other,,
340,949256,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: R030409,Other,,
341,949257,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: R030409,Other,,
342,949960,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: R030409,Other,,
343,949961,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: R030409,Other,,
344,949962,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: R030409,Other,,
345,949963,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: R030409,Other,,
346,949964,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: R030409,Other,,
347,949965,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: R030409,Other,,
348,949966,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: R030409,Other,,
349,949967,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: R030409,Other,,
350,949968,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: R030409,Other,,
351,949969,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: R030409,Other,,
352,949970,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: R030409,Other,,
353,949971,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: R030409,Other,,
354,949972,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: R030409,Other,,
355,949973,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: R030409,Other,,
356,949974,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: R030409,Other,,
357,951996,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: R030409,Other,,
358,951997,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: R030409,Other,,
359,951998,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: R030409,Other,,
360,951999,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: R030409,Other,,
361,952000,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: R030409,Other,,
362,952001,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: R030409,Other,,
363,952632,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: R030409,Other,,
364,952633,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: R030409,Other,,
365,952634,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: R030409,Other,,
366,952635,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: R030409,Other,,
367,952636,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: R030409,Other,,
368,952637,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: R030409,Other,,
369,952638,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: R030409,Other,,
370,952639,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: R030409,Other,,
371,952640,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: R030409,Other,,
372,952641,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: R030409,Other,,
373,952642,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: R030409,Other,,
374,952643,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: R030409,Other,,
375,952644,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: R030409,Other,,
376,952645,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: R030409,Other,,
377,952646,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: R030409,Other,,
378,962207,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: R030409,Other,,
379,963934,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: R030409,Other,,
380,963935,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: R030409,Other,,
381,963936,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: R030409,Other,,
382,963937,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: R030409,Other,,
383,963938,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: R030409,Other,,
384,963939,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: R030409,Other,,
385,963940,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: R030409,Other,,
386,963941,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: R030409,Other,,
387,963942,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: R030409,Other,,
388,963943,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: R030409,Other,,
389,963944,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: R030409,Other,,
390,963945,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: R030409,Other,,
391,963946,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: R030409,Other,,
392,963947,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: R030409,Other,,
393,963948,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: R030409,Other,,
394,963949,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: R030409,Other,,
395,963950,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: R030409,Other,,
396,965032,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: R030916,Other,,
397,965033,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: R030916,Other,,
398,965034,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: R030916,Other,,
399,965035,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: R030916,Other,,
400,965036,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: R030916,Other,,
401,965037,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: R030916,Other,,
402,965038,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: R030916,Other,,
403,965039,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: R030916,Other,,
404,965040,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: R030916,Other,,
405,965041,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: R030916,Other,,
406,965042,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: R030916,Other,,
407,965043,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: R030916,Other,,
408,965044,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: R030916,Other,,
409,965045,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: R030916,Other,,
410,965046,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: R030916,Other,,
411,972575,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: R030916,Other,,
412,972576,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: R030916,Other,,
413,972577,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: R030916,Other,,
414,972578,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: R030916,Other,,
415,972579,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: R030916,Other,,
416,972580,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: R030916,Other,,
417,974606,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: R030916,Other,,
418,974607,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: R030916,Other,,
419,974608,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: R030916,Other,,
420,974609,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: R030916,Other,,
421,974610,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: R030916,Other,,
422,974611,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: R030916,Other,,
423,974612,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: R030916,Other,,
424,974613,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: R030916,Other,,
425,974614,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: R030916,Other,,
426,977940,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: R030409",Other,,
427,977941,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: R030409",Other,,
428,981434,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: R030409",Other,,
429,981435,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: R030409",Other,,
430,981902,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: R030409",Other,,
431,983928,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: R030409",Other,,
432,983929,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: R030409",Other,,
433,983930,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: R030409",Other,,
434,983931,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: R030409",Other,,
435,983932,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: R030409,Other,,
436,983933,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: R030409",Other,,
437,983934,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: R030409,Other,,
438,983935,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: R030409",Other,,
439,983936,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: R030409",Other,,
440,983937,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: R030409",Other,,
441,983938,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: R030409",Other,,
442,983939,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: R030409",Other,,
443,983940,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: R030409",Other,,
444,983941,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: R030409",Other,,
445,983942,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: R030409",Other,,
446,983943,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: R030409",Other,,
447,983944,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: R030409",Other,,
448,983945,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: R030409",Other,,
449,983946,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: R030409",Other,,
450,983947,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: R030409",Other,,
451,983948,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: R030409",Other,,
452,983949,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: R030409",Other,,
453,983950,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: R030409",Other,,
454,983951,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: R030409",Other,,
455,983952,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: R030409",Other,,
456,983953,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: R030409,Other,,
457,983954,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: R030409",Other,,
458,983955,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: R030409",Other,,
459,983956,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: R030409",Other,,
460,983957,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: R030409",Other,,
461,983958,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: R030409",Other,,
462,983959,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: R030409",Other,,
463,984429,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: R030409",Other,,
464,984430,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: R030409",Other,,
465,984431,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: R030409,Other,,
466,984432,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: R030409",Other,,
467,984433,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: R030409",Other,,
468,984434,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: R030409",Other,,
469,984435,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: R030409",Other,,
470,984436,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: R030409",Other,,
471,984437,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: R030409",Other,,
472,984438,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: R030409",Other,,
473,984439,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: R030409,Other,,
474,984440,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: R030409",Other,,
475,984441,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: R030409",Other,,
476,984442,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: R030409",Other,,
477,984443,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: R030409,Other,,
478,984444,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: R030409",Other,,
479,984445,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: R030409",Other,,
480,984446,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: R030409",Other,,
481,984447,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: R030409",Other,,
482,984448,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: R030409",Other,,
483,984449,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: R030409",Other,,
484,984450,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 28 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: R030409",Other,,
485,984451,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: R030409",Other,,
486,984452,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: R030409",Other,,
487,984453,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: R030409",Other,,
488,984454,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: R030409",Other,,
489,984455,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: R030409,Other,,
490,984456,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: R030409",Other,,
491,984457,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: R030409,Other,,
492,984458,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: R030409",Other,,
493,984459,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: R030409",Other,,
494,984460,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: R030409",Other,,
495,984461,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: R030409",Other,,
496,984462,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: R030409",Other,,
497,984463,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: R030409",Other,,
498,984464,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: R030409",Other,,
499,984465,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: R030409",Other,,
500,984466,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: R030409",Other,,
501,984467,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: R030409",Other,,
502,984934,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: R030409",Other,,
503,984935,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: R030409",Other,,
504,984936,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: R030409",Other,,
505,984937,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: R030409",Other,,
506,984938,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: R030409",Other,,
507,984939,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: R030409",Other,,
508,984940,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: R030409",Other,,
509,984941,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: R030409",Other,,
510,984942,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: R030409",Other,,
511,985449,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: R030409",Other,,
512,985450,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: R030409",Other,,
513,985451,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: R030409,Other,,
514,985452,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: R030409",Other,,
515,985453,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: R030409",Other,,
516,985454,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: R030409",Other,,
517,985455,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: R030409",Other,,
518,985456,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: R030409",Other,,
519,985457,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: R030409",Other,,
520,985458,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: R030409",Other,,
521,985459,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: R030409,Other,,
522,985460,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: R030409",Other,,
523,985461,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: R030409",Other,,
524,985462,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: R030409",Other,,
525,985463,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: R030409",Other,,
526,985464,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: R030409",Other,,
527,985465,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: R030409",Other,,
528,985466,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: R030409",Other,,
529,985467,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: R030409",Other,,
530,985468,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: R030409",Other,,
531,985469,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: R030409",Other,,
532,985470,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: R030409,Other,,
533,985471,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: R030409",Other,,
534,985472,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: R030409",Other,,
535,985473,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: R030409,Other,,
536,985474,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: R030409",Other,,
537,985475,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: R030409",Other,,
538,985476,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: R030409",Other,,
539,985477,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: R030409",Other,,
540,1027120,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: R030409",Other,,
541,1027121,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: R030409",Other,,
542,1027122,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: R030409",Other,,
543,1027123,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: R030409",Other,,
544,1027124,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: R030409",Other,,
545,1027125,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: R030409",Other,,
546,1027126,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: R030409",Other,,
547,1027127,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: R030409,Other,,
548,1027128,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: R030409",Other,,
549,1027129,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: R030409,Other,,
550,1027130,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: R030409",Other,,
551,1027131,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: R030409",Other,,
552,1027132,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: R030409",Other,,
553,1027133,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: R030409",Other,,
554,1027134,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: R030409",Other,,
555,1027135,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: R030409",Other,,
556,1027136,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: R030409",Other,,
557,1027137,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: R030409",Other,,
558,1027138,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: R030409",Other,,
559,1027139,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: R030409",Other,,
560,1027140,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: R030409",Other,,
561,1027141,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: R030409",Other,,
562,1027142,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: R030409",Other,,
563,1027143,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: R030409",Other,,
564,1027144,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: R030409",Other,,
565,1027145,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: R030409",Other,,
566,1027146,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: R030409",Other,,
567,1027147,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: R030409",Other,,
568,1027148,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: R030409,Other,,
569,1027149,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: R030409",Other,,
570,1027150,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: R030409",Other,,
571,1027151,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: R030409",Other,,
572,1027152,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: R030409",Other,,
573,1027153,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: R030409",Other,,
574,1027154,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: R030409",Other,,
575,1029610,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: R030409",Other,,
576,1029611,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: R030409",Other,,
577,1029612,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: R030409",Other,,
578,1029613,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: R030409",Other,,
579,1029614,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: R030409,Other,,
580,1029615,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: R030409",Other,,
581,1029616,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: R030409",Other,,
582,1029617,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: R030409",Other,,
583,1029618,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: R030409",Other,,
584,1029619,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: R030409",Other,,
585,1029620,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: R030409",Other,,
586,1029621,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: R030409",Other,,
587,1029622,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: R030409,Other,,
588,1029623,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: R030409",Other,,
589,1029624,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: R030409",Other,,
590,1029625,1,3,,103204055,15625,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: R030409,Other,,
591,1029626,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: R030409",Other,,
592,1029627,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: R030409",Other,,
593,1029628,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: R030409",Other,,
594,1029629,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: R030409",Other,,
595,1029630,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: R030409",Other,,
596,1029631,1,3,,103204055,15625,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 91 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: R030409",Other,,
597,1141941,1,3,,103204055,15625,Active,29337198.0,11622.0,,,Agonist activity at AHR in FVB/N mouse primary mammary epithelial cells assessed as upregulation of desmoglein-3 protein level at 10 nM after 144 hrs by Western blot analysis in presence of FGF2,Other,24767852.0,
598,1159509,1,1,,144209990,15625,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
599,1159515,1,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
600,1159516,1,1,,144209990,15625,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
601,1159517,1,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
602,1159518,1,1,,144209990,15625,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
603,1159519,1,1,,144209990,15625,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
604,1159520,1,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
605,1159521,1,1,,144209990,15625,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
606,1159523,1,1,,144209990,15625,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
607,1159525,1,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
608,1159526,1,1,,144209990,15625,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
609,1159527,1,1,,144209990,15625,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
610,1159528,1,1,,144209990,15625,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
611,1159529,1,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
612,1159531,1,1,,144209990,15625,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
613,1159551,1,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
614,1159552,1,1,,144209990,15625,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
615,1159553,2,1,,144209990,15625,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
616,1159555,1,1,,144209990,15625,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
617,1182268,1,1,,103204055,15625,Unspecified,,,,,Half life in human,Other,24997686.0,
618,1224834,3,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
619,1224835,1,1,,144209990,15625,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
620,1224836,1,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
621,1224837,1,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
622,1224838,1,1,,144209990,15625,Inactive,66775687.0,9970.0,0.0038,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
623,1224839,1,1,,144209990,15625,Inconclusive,66775687.0,9970.0,0.0211,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
624,1224840,3,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
625,1224841,3,1,,144209990,15625,Inconclusive,325495545.0,2101.0,0.0003,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
626,1224842,3,1,,144209990,15625,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
627,1224843,1,1,,144209990,15625,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
628,1224844,1,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
629,1224845,1,1,,144209990,15625,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
630,1224846,1,1,,144209990,15625,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
631,1224847,1,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
632,1224848,3,1,,144209990,15625,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
633,1224849,3,1,,144209990,15625,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
634,1224867,1,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
635,1224868,1,1,,144209990,15625,Inconclusive,,,0.2132,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
636,1224869,1,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
637,1224870,1,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
638,1224871,1,1,,144209990,15625,Inactive,,,0.2392,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
639,1224872,1,1,,144209990,15625,Inconclusive,,,0.2132,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
640,1224873,1,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
641,1224874,1,1,,144209990,15625,Inconclusive,,,0.2132,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
642,1224875,1,1,,144209990,15625,Inactive,,,0.2392,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
643,1224876,1,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
644,1224877,1,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
645,1224878,1,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
646,1224879,1,1,,144209990,15625,Active,,,0.0268,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
647,1224880,1,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
648,1224881,1,1,,144209990,15625,Inactive,,,0.2392,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
649,1224882,1,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
650,1224883,1,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
651,1224884,1,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
652,1224885,1,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
653,1224886,1,1,,144209990,15625,Inconclusive,,,0.2132,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
654,1224887,1,1,,144209990,15625,Inconclusive,,,0.2132,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
655,1224888,1,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
656,1224889,1,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
657,1224890,1,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
658,1224892,1,1,,144209990,15625,Active,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
659,1224893,1,1,,144209990,15625,Inconclusive,66775687.0,9970.0,0.00530858,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
660,1224894,1,1,,144209990,15625,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
661,1224895,1,1,,144209990,15625,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
662,1224896,1,1,,144209990,15625,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
663,1259241,1,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
664,1259242,1,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
665,1259243,1,1,,144209990,15625,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
666,1259244,1,1,,144209990,15625,Inconclusive,348019627.0,2099.0,0.006,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
667,1259247,1,1,,144209990,15625,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
668,1259248,1,1,,144209990,15625,Active,348019627.0,2099.0,0.00390521,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
669,1259364,1,1,,144209990,15625,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
670,1259365,1,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
671,1259366,1,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
672,1259367,1,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
673,1259368,1,1,,144209990,15625,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
674,1259369,1,1,,144209990,15625,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
675,1259377,1,1,,144209990,15625,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
676,1259378,1,1,,144209990,15625,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
677,1259379,1,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
678,1259380,1,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
679,1259381,1,1,,144209990,15625,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
680,1259382,1,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
681,1259383,1,1,,144209990,15625,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
682,1259384,1,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
683,1259385,1,1,,144209990,15625,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
684,1259386,1,1,,144209990,15625,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
685,1259387,1,1,,144209990,15625,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
686,1259388,1,1,,144209990,15625,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
687,1259390,1,1,,144209990,15625,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
688,1259391,1,1,,144209990,15625,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
689,1259392,1,1,,144209990,15625,Inconclusive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
690,1259393,1,1,,144209990,15625,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
691,1259394,1,1,,144209990,15625,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
692,1259395,1,1,,144209990,15625,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
693,1259396,1,1,,144209990,15625,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
694,1259401,1,1,,144209990,15625,Active,325495545.0,2101.0,0.00354796,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
695,1259402,1,1,,144209990,15625,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
696,1259403,1,1,,144209990,15625,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
697,1259404,1,1,,144209990,15625,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
698,1259407,1,1,,363898526,15625,Inactive,,,,,CCRIS mutagenicity studies,Other,,
699,1259408,1,1,,363896092,15625,Active,,,,,GENE-TOX mutagenicity studies,Other,,
700,1259409,1,1,,363898526,15625,Unspecified,,,,,CCRIS tumor inhibitor studies,Other,,
701,1259410,1,1,,363898526,15625,Unspecified,,,,,CCRIS tumor promotion studies,Other,,
702,1259411,1,1,,363898526,15625,Active,,,,,CCRIS carcinogenicity studies,Other,,
